Pharmaceutical intermediates
Elacestrant Intermediates
8 pharmaceutical intermediates for Elacestrant. Indication: Breast Neoplasms, Metastatic breast cancer.
About Elacestrant
- Originator
- Eisai
- Indication
- Breast Neoplasms, Metastatic breast cancer
- Approved Date
- 01/27/2023
- NCE Patent
- 12/25/2025
- DS/DP
- 01/27/2028
Available intermediates
8 intermediates currently listed for Elacestrant. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 6-(benzyloxy)-3,4-dihydronaphthalen-1(2H)-one | 32263-70-0 | / | / |
| 7-(benzyloxy)-3-bromo-1,2-dihydronaphthalene | 722536-73-4 | / | / |
| 2-(6-(benzyloxy)-3,4-dihydronaphthalen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane | 2477812-43-2 | / | / |
| 6-(2-amino-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol | 722520-36-7 | / | / |
| (R)-6-(2-amino-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol | 2477812-39-6 | / | / |
| N-ethyl-2-(4-formylphenyl)acetamide | 2477812-42-1 | / | / |
| 2-Bromo-5-Methoxyaniline | 59557-92-5 | / | / |
| 2-Bromo-5-methoxyanilinehydrochloride | 129968-11-2 | / | / |
Building toward Elacestrant?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →